Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports First Quarter 2015 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/5/2026

1. KRG
2. SPY
3. ALAR
4. SKA-B
5. PBA
6. CCH:LN
7. META
8. BAJAJHFL:I
9. CCHGY
10. PRY:IM

Go back to Esperion Therapeutics Provides ETC-1002 Development Program Update; Reports First Quarter 2015 Financial Results

Esperion Therapeutics (ESPR) PT Raised to $130 at Needham & Company

May 8, 2015 7:46 AM EDT

Needham & Company analyst Chad Messer reiterated a Buy rating and boosted his price target on Esperion Therapeutics (NASDAQ: ESPR) to $130.00 (from $104.00), citing multiple value-creating events through year-end.

Esperion has submitted briefing documents to the FDA and expects to be able to hold... More

Esperion Therapeutics (ESPR) Misses Q1 EPS by 8c

May 7, 2015 5:02 PM EDT

Esperion Therapeutics (NASDAQ: ESPR) reported Q1 EPS of ($0.56), $0.08 worse than the analyst estimate of ($0.48).

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

... More